$BMRN
BIOMARIN PHARMACEUTICAL INC Stock $bmrn

$bmrn Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000104847721000008 Filed on February 26, 2021

Income Statement

Concept	2019 Q4	2018 Q4	2018
Revenue	$454.4M	$353.2M	$1.491B
YoY Change	28.65%	-1.42%	13.52%
Cost Of Revenue	$95.90M	$75.00M	$315.3M
YoY Change	27.87%	-1.32%	30.39%
Gross Profit	$358.5M	$278.2M	$1.176B
YoY Change	28.86%	-1.45%	9.71%
Gross Profit Margin	78.9%	78.77%	78.86%
Selling, General & Admin	$187.8M	$168.7M	$604.4M
YoY Change	11.32%	4.52%	9.02%
% of Gross Profit	52.38%	60.64%	51.39%
Research & Development	$172.8M	$175.4M	$696.3M
YoY Change	-1.48%	4.03%	14.01%
% of Gross Profit	48.2%	63.05%	59.21%
Depreciation & Amortization	$25.80M	$24.70M	$95.67M
YoY Change	4.45%	-13.94%	8.89%
% of Gross Profit	7.2%	8.88%	8.14%
Operating Expenses	$376.9M	$351.7M	$1.301B
YoY Change	7.17%	2.36%	11.64%
Operating Profit	-$18.40M	-$73.50M	-$123.5M
YoY Change	-74.97%	19.9%	740.3%
Interest Expense	-$2.300M	$3.200M	$43.66M
YoY Change	-171.88%	-125.0%	2.24%
% of Operating Profit
Other Income/Expense, Net	$900.0K	-$3.100M	$2.200M
YoY Change	-129.03%	-183.78%	-72.5%
Pretax Income	-$9.800M	-$43.30M	-$142.7M
YoY Change	-77.37%	-179.3%	297.78%
Income Tax	-$24.80M	-$44.30M	-$65.49M
% Of Pretax Income
Net Earnings	$15.00M	-$3.700M	-$77.21M
YoY Change	-505.41%	-92.8%	-34.03%
Net Earnings / Revenue	3.3%	-1.05%	-5.18%
Basic Earnings Per Share			-$0.44
Diluted Earnings Per Share	$83.57K	-$20.80K	-$0.44
COMMON SHARES
Basic Shares Outstanding	179.6M shares		177.1M shares
Diluted Shares Outstanding			177.3M shares

Balance Sheet

Concept	2019 Q4	2018 Q4	2018
SHORT-TERM ASSETS
Cash & Short-Term Investments	$753.8M	$1.084B	$1.084B
YoY Change	-30.48%	-22.33%	-22.33%
Cash & Equivalents	$437.4M	$494.0M	$494.0M
Short-Term Investments	$316.4M	$590.3M	$590.3M
Other Short-Term Assets	$130.7M	$98.40M	$98.40M
YoY Change	32.78%	32.91%	32.97%
Inventory	$680.3M	$530.9M	$530.9M
Prepaid Expenses
Receivables	$377.4M	$342.6M	$342.6M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.942B	$2.056B	$2.056B
YoY Change	-5.55%	-6.84%	-6.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.011B	$948.7M	$948.7M
YoY Change	6.55%	5.8%	5.8%
Goodwill	$197.0M	$197.0M
YoY Change	0.0%
Intangibles	$456.6M	$491.8M
YoY Change	-7.16%
Long-Term Investments	$412.0M	$235.9M	$235.9M
YoY Change	74.65%	-38.85%	-38.85%
Other Assets	$122.0M	$36.57M	$497.5M
YoY Change	233.65%	-91.47%	15.99%
Total Long-Term Assets	$2.748B	$2.371B	$2.371B
YoY Change	15.9%	-2.27%	-2.27%
TOTAL ASSETS
Total Short-Term Assets	$1.942B	$2.056B	$2.056B
Total Long-Term Assets	$2.748B	$2.371B	$2.371B
Total Assets	$4.690B	$4.427B	$4.427B
YoY Change	5.94%	-4.45%	-4.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$241.0M	$208.1M	$208.1M
YoY Change	15.81%	28.7%	28.7%
Accrued Expenses	$287.9M	$213.0M	$213.0M
YoY Change	35.16%	5.65%	5.65%
Deferred Revenue	$13.04M	$1.467M
YoY Change	788.68%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$365.1M	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$932.5M	$523.2M	$523.2M
YoY Change	78.22%	-35.92%	-35.92%
LONG-TERM LIABILITIES
Long-Term Debt	$492.9M	$830.4M	$830.4M
YoY Change	-40.64%	2.08%	2.08%
Other Long-Term Liabilities	$98.12M	$58.65M	$105.5M
YoY Change	67.31%	-69.83%	-45.73%
Total Long-Term Liabilities	$98.12M	$58.65M	$935.9M
YoY Change	67.31%	-94.18%	-7.14%
TOTAL LIABILITIES
Total Short-Term Liabilities	$932.5M	$523.2M	$523.2M
Total Long-Term Liabilities	$98.12M	$58.65M	$935.9M
Total Liabilities	$1.568B	$1.459B	$1.459B
YoY Change	7.43%	-20.02%	-20.02%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.721B	-$1.694B
YoY Change	1.57%
Common Stock	$4.833B	$4.670B
YoY Change	3.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.122B	$2.968B	$2.968B
YoY Change
Total Liabilities & Shareholders Equity	$4.690B	$4.427B	$4.427B
YoY Change	5.94%	-4.45%	-4.45%

Cashflow Statement

Concept	2019 Q4	2018 Q4	2018
OPERATING ACTIVITIES
Net Income	$15.00M	-$3.700M	-$77.21M
YoY Change	-505.41%	-92.8%	-34.03%
Depreciation, Depletion And Amortization	$25.80M	$24.70M	$95.67M
YoY Change	4.45%	-13.94%	8.89%
Cash From Operating Activities	$57.40M	$49.40M	$20.21M
YoY Change	16.19%	238.36%	-330.76%
INVESTING ACTIVITIES
Capital Expenditures	-$60.80M	-$42.10M	$144.6M
YoY Change	44.42%	5.51%	-27.41%
Acquisitions			$0.00
YoY Change
Other Investing Activities	$12.00M	-$28.90M	$10.00K
YoY Change	-141.52%	-116.1%	-99.43%
Cash From Investing Activities	-$48.90M	-$70.90M	$264.4M
YoY Change	-31.03%	-150.82%	-186.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.000M	-366.4M	-$388.0M
YoY Change	-101.09%	-2896.95%	-176.51%
NET CHANGE
Cash From Operating Activities	57.40M	49.40M	$20.21M
Cash From Investing Activities	-48.90M	-70.90M	$264.4M
Cash From Financing Activities	4.000M	-366.4M	-$388.0M
Net Change In Cash	12.50M	-387.9M	-$104.0M
YoY Change	-103.22%	-332.0%	-154.85%
FREE CASH FLOW
Cash From Operating Activities	$57.40M	$49.40M	$20.21M
Capital Expenditures	-$60.80M	-$42.10M	$144.6M
Free Cash Flow	$118.2M	$91.50M	-$124.4M
YoY Change	29.18%	67.89%	-40.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001048477
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:OtherAssetsNoncurrent
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:OtherAssetsNoncurrent
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:OtherAssetsNoncurrent
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:OtherAssetsNoncurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
CY2019Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
CY2019Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
CY2020Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	000-26727
CY2020	dei	Entity Registrant Name EntityRegistrantName	BioMarin Pharmaceutical Inc
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	68-0397820
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	770 Lindaro Street
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	San Rafael
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94901
CY2020	dei	City Area Code CityAreaCode	415
CY2020	dei	Local Phone Number LocalPhoneNumber	506-6700
CY2020	dei	Security12b Title Security12bTitle	Common Stock, par value $.001
CY2020	dei	Trading Symbol TradingSymbol	BMRN
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	13900000000	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	181829680	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	649158000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	437446000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	416228000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	316361000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	448351000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	377404000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	698548000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	680275000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	129934000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	130657000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	2342219000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	1942143000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	285473000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	411978000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1032471000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1010868000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	417271000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	456580000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	196199000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	197039000	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1432150000	USD
CY2019Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	549422000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	142237000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	122009000	USD
CY2020Q4	us-gaap	Assets Assets	5848020000	USD
CY2019Q4	us-gaap	Assets Assets	4690039000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	492548000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	570621000	USD
CY2020Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	USD
CY2019Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	361882000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	492548000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	932503000	USD
CY2020Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1075145000	USD
CY2019Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	486238000	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	60130000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	50793000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	114195000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	98124000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	1742018000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	1567658000	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	181740999	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	181740999	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	179838114	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	179838114	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	182000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	180000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	4993407000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	4832707000	USD
CY2020Q4	us-gaap	Common Stock Issued Employee Stock Trust CommonStockIssuedEmployeeStockTrust	9839000	USD
CY2019Q4	us-gaap	Common Stock Issued Employee Stock Trust CommonStockIssuedEmployeeStockTrust	9961000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-16139000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	20164000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-861609000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1720709000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	4106002000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	3122381000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5848020000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4690039000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1860455000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1704048000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1491212000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	680924000	USD
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	524272000	USD
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	359466000	USD
CY2018	us-gaap	Cost Of Revenue CostOfRevenue	315264000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	628116000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	715007000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	696328000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	737669000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	604353000	USD
CY2020	bmrn	Intangible Asset Amortization And Contingent Consideration IntangibleAssetAmortizationAndContingentConsideration	66658000	USD
CY2019	bmrn	Intangible Asset Amortization And Contingent Consideration IntangibleAssetAmortizationAndContingentConsideration	74108000	USD
CY2018	bmrn	Intangible Asset Amortization And Contingent Consideration IntangibleAssetAmortizationAndContingentConsideration	48791000	USD
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	59495000	USD
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	25000000	USD
CY2018	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	50000000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	1897220000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	1804505000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	1614736000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-123524000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-36765000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-100457000	USD
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-6000	USD
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-587000	USD
CY2018	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-553000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	16610000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	22748000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	22831000	USD
CY2020	us-gaap	Interest Expense InterestExpense	29309000	USD
CY2019	us-gaap	Interest Expense InterestExpense	23460000	USD
CY2018	us-gaap	Interest Expense InterestExpense	43664000	USD
CY2020	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	7148000	USD
CY2019	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	6945000	USD
CY2018	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	2205000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-42322000	USD
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	177061000	shares
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-94811000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-142705000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-901422000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-70963000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-65494000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	859100000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-23848000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-77211000	USD
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.75
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.53
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	180804000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	179039000	shares
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	324000	USD
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	191678000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	179039000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	177268000	shares
CY2020	us-gaap	Net Income Loss NetIncomeLoss	859100000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-23848000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-77211000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	227000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	1640000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	413000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	749000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5482000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1391000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	127000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0	USD
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	425000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	5482000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1391000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax	0	USD
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	-23462000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	25266000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	25386000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax	0	USD
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax	0	USD
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	13180000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	15853000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	-2047000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent	-36642000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent	9413000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	159865000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent	27433000	USD
CY2020	bmrn	Other Comprehensive Income Loss Other Net Of Tax OtherComprehensiveIncomeLossOtherNetOfTax	15000	USD
CY2019	bmrn	Other Comprehensive Income Loss Other Net Of Tax OtherComprehensiveIncomeLossOtherNetOfTax	-2000	USD
CY2018	bmrn	Other Comprehensive Income Loss Other Net Of Tax OtherComprehensiveIncomeLossOtherNetOfTax	-6000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-36303000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	14893000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	28818000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	822797000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8955000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48393000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	3122381000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	2967940000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	2808663000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-36303000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	14893000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	28818000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	105172000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	4106002000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	3122381000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	2967940000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	859100000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-23848000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-77211000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	105300000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	95671000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	16511000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	13960000	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	31186000	USD
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-567000	USD
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2000000	USD
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-358000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	189711000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	148819000	USD
CY2020	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	59495000	USD
CY2019	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	25000000	USD
CY2018	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	50000000	USD
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	75609000	USD
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2018	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-888907000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-82760000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-68378000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-8011000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-1025000	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	17766000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	4500000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5205000	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	9296000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	997000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2393000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2347000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	59035000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	37852000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	54274000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	61151000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	107554000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	23747000	USD
CY2020	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-18312000	USD
CY2019	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	27008000	USD
CY2018	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	17767000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	28647000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	8895000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	935000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-87025000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	77089000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	38389000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-6871000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	3128000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	8914000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	85365000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	48262000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	20208000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	114312000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	145026000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	144620000	USD
CY2020	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	555834000	USD
CY2019	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	740211000	USD
CY2018	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	993734000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	529663000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	632023000	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	18380000	USD
CY2018	bmrn	Payments To Acquire Debt Securities Available For Sale Non Marketable PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable	0	USD
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	634753000	USD
CY2020	bmrn	Proceeds From Sale Of Nonfinancial Assets ProceedsFromSaleOfNonfinancialAssets	67159000	USD
CY2019	bmrn	Proceeds From Sale Of Nonfinancial Assets ProceedsFromSaleOfNonfinancialAssets	25000000	USD
CY2018	bmrn	Proceeds From Sale Of Nonfinancial Assets ProceedsFromSaleOfNonfinancialAssets	50000000	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	23207000	USD
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2020	bmrn	Payments To Acquire Debt Securities Available For Sale Non Marketable PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable	8709000	USD
CY2019	bmrn	Payments To Acquire Debt Securities Available For Sale Non Marketable PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable	0	USD
CY2020	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	723000	USD
CY2019	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	808000	USD
CY2018	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	10000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-53621000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-31026000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	264351000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	71913000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	31611000	USD
CY2018	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	67488000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	44638000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	42680000	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	35919000	USD
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	50000000	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	585752000	USD
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2018	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2020	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	374991000	USD
CY2019	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2018	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	374953000	USD
CY2020	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	181118000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-74674000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-388007000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1150000	USD
CY2019	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	58518000	USD
CY2018	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	44623000	USD
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-6918000	USD
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-5087000	USD
CY2018	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	902000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-598000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	211712000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-56536000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-104046000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	437446000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	493982000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	598028000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	649158000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	437446000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	493982000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	12178000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	8552000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	11623000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	8977000	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	9726000	USD
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	16676000	USD
CY2020	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Fixed Assets SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets	-5184000	USD
CY2019	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Fixed Assets SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets	7589000	USD
CY2018	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Fixed Assets SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets	-1206000	USD
CY2020	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Intangible Assets SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets	-292000	USD
CY2019	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Intangible Assets SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets	4247000	USD
CY2018	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Intangible Assets SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets	0	USD
CY2020	us-gaap	Nature Of Operations NatureOfOperations	NATURE OF OPERATIONS AND BUSINESS RISKS<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BioMarin Pharmaceutical Inc. (the Company or BioMarin) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s portfolio consists of several commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents and investments and through proceeds from debt or equity offerings, commercial borrowing, or through collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is subject to a number of risks, including: the continuing impact of the novel coronavirus disease (referred to as COVID-19) pandemic on the Company's business; the financial performance of its commercial products; the potential need for additional financing; the Company’s ability to successfully commercialize its approved products; the uncertainty of the Company’s research and development efforts resulting in future successful commercial products; the Company’s ability to successfully obtain regulatory approval for new products; significant competition from larger organizations; reliance on the proprietary technology of others; dependence on key personnel; uncertain patent protection; dependence on corporate partners and collaborators; and possible restrictions on reimbursement from governmental agencies and healthcare organizations, as well as other changes in the healthcare industry.</span></div>
CY2020	us-gaap	Basis Of Accounting BasisOfAccounting	BASIS OF PRESENTATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Annual Reports on Form 10-K and include the accounts of BioMarin and its wholly owned subsidiaries. All intercompany transactions have been eliminated. Management performed an evaluation of the Company’s activities through the date of filing of this Annual Report on Form 10-K, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date and prior to the filing of this Annual Report on Form 10-K that would require recognition or disclosure in the Consolidated Financial Statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 1, 2020, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (ASU 2016-13), as amended, using a modified retrospective approach. The standard has amended the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary impairment model. Results for reporting periods beginning January 1, 2020 are presented under ASU 2016-13 and the adoption of this standard had no impact on the Company’s Financial Statements. See Note 4 to these Consolidated Financial Statements for additional discussion of the adoption of ASU 2016-13 and required disclosures.</span></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Company’s Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that are highly </span></div>uncertain at this time. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods.
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Company’s Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that are highly </span></div>uncertain at this time. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods.
CY2020Q4	bmrn	Number Of Tranches In Offering Period NumberOfTranchesInOfferingPeriod	4	tranche
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	Segment
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1345801000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5069000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	11000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1350859000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	649158000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	416228000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	285473000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1161152000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4713000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	80000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1165785000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	437446000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	316361000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	411978000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	197039000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	197039000	USD
CY2020	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	840000	USD
CY2019	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	0	USD
CY2020Q4	us-gaap	Goodwill Goodwill	196199000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	197039000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	644087000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	652734000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	226816000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	196154000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	417271000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	456580000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	417271000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	94606000	USD
CY2020Q4	bmrn	Finite Lived Intangible Assets Amortization Not Commenced Net FiniteLivedIntangibleAssetsAmortizationNotCommencedNet	370614000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	61963000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	61939000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	61311000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	55036000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	35759000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1668066000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1559968000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	635595000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	549100000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1032471000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1010868000	USD
CY2020	us-gaap	Depreciation Depreciation	88169000	USD
CY2019	us-gaap	Depreciation Depreciation	89285000	USD
CY2018	us-gaap	Depreciation Depreciation	90375000	USD
CY2020	bmrn	Depreciation Expense Capitalized Into Inventory DepreciationExpenseCapitalizedIntoInventory	44492000	USD
CY2019	bmrn	Depreciation Expense Capitalized Into Inventory DepreciationExpenseCapitalizedIntoInventory	37481000	USD
CY2018	bmrn	Depreciation Expense Capitalized Into Inventory DepreciationExpenseCapitalizedIntoInventory	25227000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	76673000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	74442000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	308286000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	349978000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	313589000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	255855000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	698548000	USD
CY2020Q4	bmrn	Accrued Government And Other Rebates AccruedGovernmentAndOtherRebates	65526000	USD
CY2019Q4	bmrn	Accrued Government And Other Rebates AccruedGovernmentAndOtherRebates	57163000	USD
CY2020Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	17798000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	680275000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	191429000	USD
CY2019Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	240981000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	165023000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	192467000	USD
CY2019Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	10448000	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	17155000	USD
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	30797000	USD
CY2020Q4	bmrn	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	11754000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	570621000	USD
CY2019Q4	bmrn	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	10700000	USD
CY2020Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	9661000	USD
CY2019Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	3195000	USD
CY2020Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	9562000	USD
CY2019Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	8395000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	152000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13037000	USD
CY2020Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	4488000	USD
CY2019Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	3438000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	492548000	USD
CY2020Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	9500000	USD
CY2019Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	33592000	USD
CY2020Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	28818000	USD
CY2019Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	15941000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	1897220000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	1804505000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7451000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2865000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	46014000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	49045000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	11095000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	10389000	USD
CY2020Q4	bmrn	Operating And Finance Lease Right Of Use Asset OperatingAndFinanceLeaseRightOfUseAsset	57109000	USD
CY2019Q4	bmrn	Operating And Finance Lease Right Of Use Asset OperatingAndFinanceLeaseRightOfUseAsset	59434000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8889000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	3249000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	40483000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44092000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4006000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	6708000	USD
CY2020Q4	bmrn	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	56243000	USD
CY2019Q4	bmrn	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	61500000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	11295000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	3095000	USD
CY2020Q4	bmrn	Operating And Finance Lease Liability Payments Due Next Twelve Months OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths	14390000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10127000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	2383000	USD
CY2020Q4	bmrn	Operating And Finance Lease Liability Payments Due Year Two OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo	12510000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8605000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	1800000	USD
CY2020Q4	bmrn	Operating And Finance Lease Liability Payments Due After Year Five OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive	16758000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	58916000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	7349000	USD
CY2020Q4	bmrn	Operating And Finance Lease Liability Payments Due Year Three OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree	10405000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6570000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	50000	USD
CY2020Q4	bmrn	Operating And Finance Lease Liability Payments Due Year Four OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour	6620000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	5561000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	21000	USD
CY2020Q4	bmrn	Operating And Finance Lease Liability Payments Due Year Five OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive	5582000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	16758000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2020Q4	bmrn	Operating And Finance Lease Liability Payments Due OperatingAndFinanceLeaseLiabilityPaymentsDue	66265000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9544000	USD
CY2020Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	478000	USD
CY2020Q4	bmrn	Operating And Finance Lease Liability Undiscounted Excess Amount OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount	10022000	USD
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y10M24D
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	10536000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	49372000	USD
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	6871000	USD
CY2020Q4	bmrn	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	56243000	USD
CY2020	us-gaap	Lease Cost LeaseCost	16560000	USD
CY2019	us-gaap	Lease Cost LeaseCost	16247000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y9M18D
CY2019Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.049
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.052
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.052
CY2019Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.054
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	450000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	8183000	USD
CY2019	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	628000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	6918000	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	5087000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4779000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	9772000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	3941000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	3267000	USD
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1100000000	USD
CY2020Q4	us-gaap	Convertible Debt ConvertibleDebt	1075145000	USD
CY2019Q4	us-gaap	Convertible Debt ConvertibleDebt	848120000	USD
CY2020Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	1157804000	USD
CY2019Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	927518000	USD
CY2018	us-gaap	Oci Before Reclassifications Before Tax Attributable To Parent OciBeforeReclassificationsBeforeTaxAttributableToParent	27184000	USD
CY2018	us-gaap	Reclassification From Aoci Current Period Before Tax Attributable To Parent ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent	-2047000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	413000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	28818000	USD
CY2019	us-gaap	Oci Before Reclassifications Before Tax Attributable To Parent OciBeforeReclassificationsBeforeTaxAttributableToParent	32386000	USD
CY2019	us-gaap	Reclassification From Aoci Current Period Before Tax Attributable To Parent ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent	15853000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	1640000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	14893000	USD
CY2020	us-gaap	Oci Before Reclassifications Before Tax Attributable To Parent OciBeforeReclassificationsBeforeTaxAttributableToParent	-22471000	USD
CY2020	us-gaap	Reclassification From Aoci Current Period Before Tax Attributable To Parent ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent	13732000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	100000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-36303000	USD
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1860455000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1704048000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1491212000	USD
CY2020Q4	us-gaap	Noncurrent Assets NoncurrentAssets	1089580000	USD
CY2019Q4	us-gaap	Noncurrent Assets NoncurrentAssets	1070302000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	36700000	shares
CY2018	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	20000000.0	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	189711000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	159865000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	148819000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	20100000	USD
CY2019	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	20300000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7264235	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	67.99
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	146700000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	891610	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	76.02
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1240511	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1438573	shares
CY2020Q4	bmrn	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice	81.56
CY2020	bmrn	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm	P8Y7M6D
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	43.87
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	85897	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	86.07
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6829437	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	73.19
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y9M18D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	119607000	USD
CY2020Q4	bmrn	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue	11635000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5390864	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	70.95
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y9M18D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	107972000	USD
CY2020Q4	us-gaap	Share Price SharePrice	87.69
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	27.47
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	36.84
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	33.40
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	71900000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	32500000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	79900000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	4500000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-162939000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-182112000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-128700000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	120617000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	87301000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-14005000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-42322000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-94811000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-142705000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-14758000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	5127000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-2660000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1201000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1331000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	588000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-72074000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-5321000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-5394000	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-994000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1042000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	5339000	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	4956000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-12515000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	11797000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2884000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-45038000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-58311000	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-838548000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-19055000	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	4690000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-888907000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-82760000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-68378000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-901422000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-70963000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-65494000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-8888000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-19911000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-29968000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3264000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2784000	USD
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-276000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	44114000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	43124000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	66451000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1101000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	239000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-5647000	USD
CY2020	bmrn	Income Tax Rate Reconciliation Changes In Fair Value Of Contingent Consideration IncomeTaxRateReconciliationChangesInFairValueOfContingentConsideration	0	USD
CY2019	bmrn	Income Tax Rate Reconciliation Changes In Fair Value Of Contingent Consideration IncomeTaxRateReconciliationChangesInFairValueOfContingentConsideration	-1804000	USD
CY2018	bmrn	Income Tax Rate Reconciliation Changes In Fair Value Of Contingent Consideration IncomeTaxRateReconciliationChangesInFairValueOfContingentConsideration	-2361000	USD
CY2020	us-gaap	Income Tax Reconciliation Repatriation Of Foreign Earnings IncomeTaxReconciliationRepatriationOfForeignEarnings	6266000	USD
CY2019	us-gaap	Income Tax Reconciliation Repatriation Of Foreign Earnings IncomeTaxReconciliationRepatriationOfForeignEarnings	-52000	USD
CY2018	us-gaap	Income Tax Reconciliation Repatriation Of Foreign Earnings IncomeTaxReconciliationRepatriationOfForeignEarnings	6543000	USD
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-16238000	USD
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-30639000	USD
CY2018	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	12583000	USD
CY2020	bmrn	Income Tax Rate Reconciliation Section162 Limitation IncomeTaxRateReconciliationSection162Limitation	9571000	USD
CY2019	bmrn	Income Tax Rate Reconciliation Section162 Limitation IncomeTaxRateReconciliationSection162Limitation	8294000	USD
CY2018	bmrn	Income Tax Rate Reconciliation Section162 Limitation IncomeTaxRateReconciliationSection162Limitation	7440000	USD
CY2020	bmrn	Income Tax Rate Reconciliation Tax Reserves IncomeTaxRateReconciliationTaxReserves	2166000	USD
CY2019	bmrn	Income Tax Rate Reconciliation Tax Reserves IncomeTaxRateReconciliationTaxReserves	12123000	USD
CY2018	bmrn	Income Tax Rate Reconciliation Tax Reserves IncomeTaxRateReconciliationTaxReserves	8545000	USD
CY2020	bmrn	Effective Income Tax Rate Reconciliation Intra Entity Transfer Of Assets Amount EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount	-852338000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4521000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7827000	USD
CY2019	bmrn	Effective Income Tax Rate Reconciliation Intra Entity Transfer Of Assets Amount EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount	0	USD
CY2018	bmrn	Effective Income Tax Rate Reconciliation Intra Entity Transfer Of Assets Amount EffectiveIncomeTaxRateReconciliationIntraEntityTransferOfAssetsAmount	0	USD
CY2020	bmrn	Effective Income Tax Rate Reconciliation Cares Act Carryback Claim EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim	2201000	USD
CY2019	bmrn	Effective Income Tax Rate Reconciliation Cares Act Carryback Claim EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim	0	USD
CY2018	bmrn	Effective Income Tax Rate Reconciliation Cares Act Carryback Claim EffectiveIncomeTaxRateReconciliationCARESActCarrybackClaim	0	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1843000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-1132000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-423000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6876000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-901422000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-70963000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-65494000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	30718000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	32181000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	532394000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	454000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	508560000	USD
CY2020Q4	bmrn	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	8991000	USD
CY2019Q4	bmrn	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	11470000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	32012000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	6290000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	66889000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	61807000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	873575000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	29413000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	47011000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	42873000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	575000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	93075000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	86197000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1498969000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	606972000	USD
CY2020Q4	bmrn	Deferred Tax Liabilities Related To Joint Venture Basis Difference DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference	1164000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	54682000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	46642000	USD
CY2019Q4	bmrn	Deferred Tax Liabilities Related To Joint Venture Basis Difference DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference	993000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1364000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1647000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Tax Deferred Income DeferredTaxLiabilitiesTaxDeferredIncome	1517000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Tax Deferred Income DeferredTaxLiabilitiesTaxDeferredIncome	3003000	USD
CY2020Q4	bmrn	Deferred Tax Liability Related To Convertible Notes DeferredTaxLiabilityRelatedToConvertibleNotes	0	USD
CY2019Q4	bmrn	Deferred Tax Liability Related To Convertible Notes DeferredTaxLiabilityRelatedToConvertibleNotes	2364000	USD
CY2020Q4	bmrn	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	8280000	USD
CY2019Q4	bmrn	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	10258000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	67007000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	64907000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1431962000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	542065000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	16481000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	19287000	USD
CY2020	bmrn	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	-2527000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	168748000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	147445000	USD
CY2019	bmrn	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	2016000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	138000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	182564000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	168748000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	175100000	USD
CY2020Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	15200000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	859100000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23848000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-77211000	USD
CY2020	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	8313000	USD
CY2019	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2018	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2020	us-gaap	Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares	0	USD
CY2019	us-gaap	Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares	0	USD
CY2018	us-gaap	Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares	-710000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	867413000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-23848000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-77921000	USD
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	180804000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	179039000	shares
CY2020	bmrn	Contingent Payments Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones	662800000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	60100000	USD
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	177061000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	191678000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	179039000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	177268000	shares
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.75
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.53
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7836000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19965000	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19156000	shares
CY2020Q4	us-gaap	Purchase Obligation PurchaseObligation	142800000	USD
CY2020Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	3700000	USD
CY2019Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	3000000.0	USD

Files In Submission

Name	View Source	Status
0001048477-21-000008-index-headers.html	Edgar Link	pending
0001048477-21-000008-index.html	Edgar Link	pending
0001048477-21-000008.txt	Edgar Link	pending
0001048477-21-000008-xbrl.zip	Edgar Link	pending
bmrn-20201231.htm	Edgar Link	pending
bmrn-20201231.xsd	Edgar Link	pending
bmrn-20201231xexx211.htm	Edgar Link	pending
bmrn-20201231xexx231.htm	Edgar Link	pending
bmrn-20201231xexx311.htm	Edgar Link	pending
bmrn-20201231xexx312.htm	Edgar Link	pending
bmrn-20201231xexx321.htm	Edgar Link	pending
bmrn-20201231_cal.xml	Edgar Link	unprocessable
bmrn-20201231_def.xml	Edgar Link	unprocessable
bmrn-20201231_g1.jpg	Edgar Link	pending
bmrn-20201231_htm.xml	Edgar Link	completed
bmrn-20201231_lab.xml	Edgar Link	unprocessable
bmrn-20201231_pre.xml	Edgar Link	unprocessable
exhibit1032.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BMRN
BIOMARIN PHARMACEUTICAL INC Stock $bmrn

2019 Q4 Form 10-K Financial Statement

#000104847721000008 Filed on February 26, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRN BIOMARIN PHARMACEUTICAL INC Stock $bmrn

2019 Q4 Form 10-K Financial Statement

#000104847721000008 Filed on February 26, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRN
BIOMARIN PHARMACEUTICAL INC Stock $bmrn